A Dose-Response Model of Local Tumor Control Probability After Stereotactic Radiosurgery for Brain Metastases Resection Cavities

Chengcheng Gui, MD, Jimm Grimm, PhD, Lawrence Richard Kleinberg, MD, Peter Zaki, MD, Nicholas Spoleti, Debraj Mukherjee, MD, MPH, Chetan Bettegowda, MD, PhD, Michael Lim, MD, and Kristin Janson Redmond, MD, MPH

Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland; Department of Radiation Oncology, University of Washington, Seattle, Washington; Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts; and Department of Neurosurgery, Johns Hopkins University, Baltimore, Maryland

Abstract

Purpose: Recent randomized controlled trials evaluating stereotactic surgery (SRS) for resected brain metastases question the high rates of local control previously reported in retrospective studies. Tumor control probability (TCP) models were developed to quantify the relationship between radiation dose and local control after SRS for resected brain metastases.

Methods and Materials: Patients with resected brain metastases treated with SRS were evaluated retrospectively. Melanoma, sarcoma, and renal cell carcinoma were considered radio-resistant histologies. The planning target volume (PTV) was the region of enhancement on T1 post-gadolinium magnetic resonance imaging plus a 2-mm uniform margin. The primary outcome was local recurrence, defined as tumor progression within the resection cavity. Cox regression evaluated predictors of local recurrence. Dose-volume histograms for the PTV were obtained from treatment plans and converted to 3-fraction equivalent doses (α/β = 12 Gy). TCP models evaluated local control at 1-year follow-up as a logistic function of dose-volume histogram data.

Results: Among 150 cavities, 41 (27.3%) were radio-resistant. The median PTV volume was 14.6 mL (range, 1.3-65.3). The median prescription was 21 Gy (range, 15-25) in 3 fractions (range, 1-5). Local control rates at 12 and 24 months were 86% and 82%. On Cox regression, larger cavities (PTV > 12 cm³) predicted increased risk of local recurrence (P < .03). TCP modeling demonstrated relationships between improved 1-year local control and higher radiation doses delivered to radio-resistant cavities. Maximum PTV doses of 30, 35, and 40 Gy predicted 78%, 89%, and 94% local control among all radio-resistant cavities, versus 69%, 79%, and 86% among larger radio-resistant cavities.

Sources of support: This study was internally funded by the Department of Radiation Oncology and Molecular Radiation Sciences at Johns Hopkins University.

Disclosures: Dr Kleinberg reports grants and personal fees from Accuray, grants from Arbor, personal fees and other from Novocure outside the submitted work. Dr Bettegowda reports grants from DePuy Synthes outside the submitted work. Dr Lim reports grants from Accuray, grants from Aegensus, grants from Altior, grants from Arbor, grants from Bristol-Myers Squibb, grants from DNAtrix, personal fees from Baxter, personal fees from SQZ Technologies, personal fees from Stryker, personal fees from Tocagen, personal fees from VBI Vaccines outside the submitted work. Dr Redmond reports grants from Elekta AB, grants and personal fees from Accuray, travel expenses from Brainlab, and DSMB for BioMimetix, outside the submitted work.

Research data are stored in an institutional repository and will be shared upon request to the corresponding author.

* Corresponding author: Kristin Redmond, MD, MPH; E-mail: kjanson3@jhmi.edu

https://doi.org/10.1016/j.adro.2020.06.007

2452-1094/© 2020 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Conclusions: After SRS for resected brain metastases, larger cavities are at greater risk of local recurrence. TCP models suggest that higher radiation doses may improve local control among cavities of radio-resistant histology. Given maximum tolerated doses established for single-fraction SRS, fractionated regimens may be required to optimize local control in large radio-resistant cavities.

Introduction

In the treatment of brain metastases after surgical resection, one of the primary motivations for choosing stereotactic radiosurgery (SRS) over whole brain radiation therapy (WBRT) is better preservation of neurocognitive function. Furthermore, many large retrospective studies have shown excellent rates of local control following SRS for resection cavities, often exceeding 80% at 1 year after treatment. In contrast, 2 randomized controlled trials recently described higher rates of local recurrence within the resection cavity than previously reported in retrospective studies, suggesting that SRS may provide inferior local control compared with WBRT. One possible explanation is that these findings reflect a need for improved target delineation. For example, larger uniform expansions of the target volume or application of advanced imaging modalities to better identify residual active tumors may be needed to improve local control. However, an alternative hypothesis is that the rates of local control in these trials reflect lower prescription doses compared with current standards. In the randomized controlled trial conducted by Mahajan et al., patients received a median dose of 16 Gy in 1 fraction (range, 12-18), compared with higher median doses in several recent retrospective studies that treated with a single fraction. Potential reasons for poorer control rates in the postoperative setting compared with intact brain metastases include greater tumor hypoxia, disruption of the tumor microenvironment, and microscopic contamination related to surgical intervention. Quantitative modeling may help to predict the effect of higher radiation doses in improving local control.

To better understand the causes of local treatment failure after SRS for resected brain metastases, this study sought to (1) investigate patient, disease, and treatment characteristics as predictors of local recurrence and (2) develop tumor control probability (TCP) models that estimate 1-year local control as a function of radiation dose to the target volume. These data demonstrate that higher doses were associated with substantially greater rates of local control among resection cavities of radio-resistant histology but not among cavities of radio-sensitive histology. Given established maximum tolerated doses (MTDs) for single-fraction treatments, these data suggest that, although single-fraction SRS may provide excellent local control for small targets, fractionated regimens may be required to optimize local control in patients with large radio-resistant cavities.

Methods and Materials

Patient, tumor, and treatment characteristics

Patients with brain metastases from solid tumors treated with surgical resection followed by frameless robotic SRS to the resection cavity at a single institution between 2011 and 2016 were eligible for inclusion if they received follow-up magnetic resonance imaging (MRI) after completion of SRS. Before data collection, institutional review board approval was obtained. Patient consent was not required to conduct this retrospective study owing to minimal risk and because a significant proportion of eligible patients were likely to be deceased at the time of data collection.

Patient, disease, and treatment characteristics were collected retrospectively. Age was defined at the time of surgical resection. Tumor histology was identified based on the surgical specimen from resection of the brain metastasis. Melanoma, sarcoma, and renal cell carcinoma were considered radio-resistant subtypes, based on a prior analysis of 83 radio-resistant brain metastases. The extent of surgical resection (gross total vs subtotal) was determined by an independent radiologist’s evaluation of the postoperative MRI, typically obtained within 24 hours of surgery. Concurrent timing of systemic therapy was defined as on the same day as SRS, in cases of daily regimens, or at least 1 cycle before SRS and at least 1 cycle after, in cases of cyclic regimens. Chemotherapy was defined as treatment with cytotoxic agents or tyrosine kinase inhibitors. Immunotherapy was defined as treatment with anti-programmed cell death protein 1 or anti-programmed death-ligand 1 agents.

SRS and dose-volume histogram analyses

All patients received SRS to the brain metastasis resection cavity in 1 to 5 consecutive daily fractions. The clinical target volume (CTV) was defined as the region of abnormality on T1 post-gadolinium MRI. The planning target volume (PTV) was typically defined per our institutional practice as a 2-mm uniform expansion of the CTV. Because the study period predates the recently

...
published consensus contouring criteria for resected brain metastases, there was no standard institutional policy regarding contouring of the surgical tract or overlying meninges.

Data obtained from SRS treatment plans included the prescribed dose and fractionation, dose-volume histogram (DVH) data, PTV volumes, percent coverage of the PTV by the prescription dose, and conformity of the dose distribution with respect to the PTV. DVH data included doses delivered to 99%, 95%, 90%, 50%, and 0.03 cm$^3$ of the PTV (D99%, D95%, D90%, D50%, D0.03 cm$^3$), and the maximum dose delivered to the PTV (Dmax). Dose conformity with respect to the PTV was evaluated by the conformity index (prescription volume/target volume) and the new conformity index.

**Local tumor recurrence and imaging follow-up**

The primary outcome was local tumor recurrence in the resection cavity, defined as fulfillment of either of 2 criteria: (1) a lesion on T1 post-gadolinium MRI overlapping the original resection cavity that was surgically resected and pathologically confirmed to be a recurrence of the original brain metastasis, or (2) a lesion on T1 post-gadolinium MRI overlapping the original resection cavity that was not resected but was judged by the patient’s oncology team based on serial MRI to be highly suspicious for recurrence, resulting in a recommendation of a second course of radiation therapy. This second course of radiation therapy could consist of either a second course of SRS or WBRT in cases of diffuse metastatic disease in addition to likely local recurrence. Follow-up MR imaging was obtained according to our institutional practice at approximately every 3 months during the first year after SRS, every 4 months during the second year, and every 6 months thereafter. Outcomes of surgical pathology were obtained from retrospective review. Specimens containing any amount of residual active tumor were considered as evidence of local treatment failure.

**Statistical analyses**

Time to local recurrence was assessed using Kaplan-Meier models, censoring at the time of last brain MRI. Univariate Cox regression was performed to assess patient, disease, and treatment characteristics as individual predictors of local recurrence. For survival analyses, tumor location was dichotomized as supratentorial versus infratentorial, and histology was dichotomized as radio-resistant versus radio-sensitive. DVH data were not included as predictors in Cox regression, as they were considered to be better evaluated within TCP models.

Multivariate Cox regression was performed to assess independent predictors of local recurrence. An initial model included all patient, disease, and treatment characteristics at least weakly associated with local recurrence on univariate Cox regression ($P < .7$). A final parsimonious model was produced by eliminating covariates that did not improve the overall model quality, as assessed by the Akaike Information Criterion. Statistical significance was defined as $P < .05$. Survival analyses were performed in R version 3.4.4.

TCP models were developed to estimate the probability of local tumor control at 1 year after SRS as a function of DVH data for the PTV. Thus, only patients who experienced local recurrence within 1 year of SRS and patients with MR imaging of the brain after minimum 1-year follow-up were analyzed in these models. As most patients received SRS in 3 fractions, DVH data for the PTV were converted to biologically equivalent doses in 3 fractions (3fxED). An $\alpha/\beta$ of 12 Gy was used, based on one of the largest meta-analyses of SRS for brain metastases published to date, which includes a quantitative dose-response analysis. The DVH evaluator tool was used to estimate the relationships between 1-year local tumor control probability and dose (3fxED) to various proportions of the PTV (D99%, D95%, D90%, D50%, D0.03 cm$^3$, Dmax) as logistic functions. Logistic dose-response relationships were estimated in this way for the overall cohort and subgroups.

**Results**

**Patient, disease, and treatment characteristics**

During the study period, 150 brain metastases in 134 patients were treated with surgical resection and SRS to the resection cavity at our institution and received follow-up MR imaging. Patient and disease characteristics are given in Table 1. The most common histologies were lung (40.7%), melanoma (12.7%), renal (12.7%), and breast (11.3%). Forty-one resected tumors (27.3%) were of radio-resistant histology.

Treatment characteristics are given in Table 2. Surgical resection was subtotal in 11 cases (7.3%) and gross total in the remainder (92.7%). Forty-two patients (28%) received chemotherapy or immunotherapy concurrently with SRS. The median prescription was 21 Gy (range, 15-25) in 3 fractions (range, 1-5). Most patients (66.7%) received radiation in 3 fractions. The median prescription isodose line was 68% (range, 50-79). The median PTV volume was 14.6 mL (range, 1.3-65.4). When stratifying by a PTV volume of 12 cm$^3$, 87 cavities (58%) were considered large and 63 cavities (42%) were considered small.

**Local tumor recurrence**

Sixteen resection cavities (10.7%) were treated with a second surgical resection for progressive enhancement on follow-up T1 post-gadolinium MRI. Upon review of
surgical specimens, 5 cases (3.3%) demonstrated radio-
necrosis and 11 cases (7.3%) demonstrated active tumor
consistent with local tumor recurrence. In addition, 9
cases (6.0%) demonstrated radiographic local recurrence
on follow-up MRI that preceded a decision to treat with a
second course of radiation therapy, but not a second
resection. Thus, 20 total cases (13.3%) of local tumor
recurrence were evaluated in this study. Actuarial rates of
local control at 6, 12, and 24 months after SRS were 92%
(95% CI = 88%-97%), 86% (95% CI = 79%-93%), and 82%
(95% CI = 74%-90%), respectively (Fig 1). Among cases in
which local recurrence was not observed, the median
time between SRS and the latest brain MRI was 12.1 months.

Greater resection cavity volume is associated with
increased risk of local recurrence

On univariate Cox regression (Table 3), large cavities
(PTV > 12 cm³) were significantly associated with local
recurrence (hazard ratio, 3.1; 95% CI = 1.1, 8.6; P = .03). Among large cavities, actuarial rates of local control
at 6, 12, and 24 months after SRS were 94% (95% CI =
88%-100%), 80% (95% CI = 69%-91%), and 71% (95% CI =
59%-86%) (Fig 1). Among small cavities (PTV <
12 cm³), the actuarial rate of local control at 6 months was
91% (95% CI = 88%-100%), and no further cases of
local recurrence were observed after 6-month follow-up
(Fig 1). Large cavities were more likely to be of breast
histology, were less likely to be of lung histology, and
received slightly lower doses (median 3fxED D95% 22.3
Gy vs 24.2 Gy among small cavities) (P < .05). Other
than PTV volume, no patient, disease, or treatment
characteristics were significantly correlated with local
recurrence on univariate Cox regression.

On multivariate Cox regression (Table 3), large cav-
ities (PTV > 12 cm³) remained significantly associated
with local recurrence (hazard ratio, 3.3; 95% CI = 1.1-
9.8; P = .03). Concurrent systemic therapy was associ-
ated with lower risk of local recurrence, and subtotal
resection was associated with greater risk of local recur-
rence, but these correlations did not reach the threshold of
statistical significance ($P = .10$, $P = .08$, respectively) (Table 3).

**Higher radiation doses are associated with improved local control among radio-resistant cavities**

Logistic regression was performed to assess relationships between DVH data (3FxED) and local tumor recurrence at 1 year after SRS. No meaningful dose-response was observed with respect to any proportion of the PTV ($D_{99\%}$, $D_{95\%}$, $D_{90\%}$, $D_{50\%}$, $D_{0.03 \text{ cm}^3}$, $D_{\text{max}}$) when evaluating the overall cohort or the subgroup of patients with radio-sensitive cavities (Fig 2 and Fig E1). However, a meaningful dose-response relationship was observed with respect to all proportions of the PTV ($D_{99\%}$, $D_{95\%}$, $D_{90\%}$, $D_{50\%}$, $D_{0.03 \text{ cm}^3}$, $D_{\text{max}}$) among patients with radio-resistant cavities (Fig 2 and Fig E2).

Further stratifying by the threshold PTV of 12 cc revealed dose-response relationships among large radio-resistant cavities, with respect to $D_{50\%}$, $D_{0.03 \text{ cm}^3}$, and $D_{\text{max}}$, but not $D_{90\%}$, $D_{95\%}$, or $D_{99\%}$ (Fig 3 and Fig E3). Furthermore, large radio-resistant cavities demonstrated lower estimated rates of local control at the same doses compared with all radio-resistant cavities, which reiterates the importance of tumor volume observed on survival analysis. Among all radio-resistant cavities, $D_{\text{max}}$ of 30, 35, and 40 Gy were associated with 69%, 79%, and 86% 1-year local control (Fig 3).

**Discussion**

In the treatment of brain metastases, retrospective studies suggest that resection followed by SRS to the cavity provides excellent local control, often exceeding 80% at 1-year follow-up. However, recent randomized controlled trials report considerably lower rates of 1-year local control, ranging from 61.8% to 72%. These findings demand a more sophisticated understanding of the factors that influence local treatment failure after resection cavity SRS. As such, we present detailed dose-response models of local tumor control probability based on one of the largest single-institution series of postoperative SRS for resected brain metastases.

Our data are consistent with prior studies reporting higher rates of local recurrence in patients with larger preoperative tumors or larger postoperative resection cavities. Specifically, PTV volumes greater than 12 cm$^3$ to 17 cm$^3$ and CTV volumes greater than 8 cm$^3$ to 10 cm$^3$ have been shown to predict greater risk of local recurrence. Similarly, we report a 3 times higher risk of local recurrence among cavities with PTV greater than 12 cm$^3$. Consequently, larger resection cavities may
require specific strategies for improving local control beyond the current standard of care.

The primary purpose of this study was to use quantitative models to describe the relationship between radiation dose and local tumor control. TCP modeling suggested that higher doses were associated with substantially greater rates of local control among resection cavities of radio-resistant histology, and particularly among large radio-resistant cavities. However, higher doses were not associated with substantially greater rates of local control among cavities of radio-sensitive histology.

These potential benefits of higher radiation doses for large and radio-resistant resection cavities should be considered in the context of MTD established for single-fraction SRS. Although single-fraction SRS may provide excellent local control for small targets, fractionated regimens may be required to optimize local control in patients with large radio-resistant cavities. However, higher doses were not associated with substantially greater rates of local control among cavities of radio-sensitive histology.

These potential benefits of higher radiation doses for large and radio-resistant resection cavities should be considered in the context of MTD established for single-fraction SRS. Although single-fraction SRS may provide excellent local control for small targets, fractionated regimens may be required to optimize local control in patients with large radio-resistant cavities. Radiation Therapy Oncology Group 90-05 provided evidence that the MTD in a single fraction for targets <2 cm, 2 to 3 cm, and 3 to 4 cm in diameter are 24, 18, and 15 Gy, respectively. In contrast, prospective data from Stanford indicates that the MTD for resection cavities between 2 and 4 cm in diameter is 30 Gy in 3 fractions, which is a higher biologically equivalent dose than 18 or 15 Gy in 1 fraction. Taken together, these studies suggest that fractionation may enable the delivery of more effective radiation doses in patients with large resection cavities.

In addition, the presence of a meaningful dose-response with respect to D50%, D0.03 cm, and Dmax suggests that selective boosting of tumor subvolumes may improve outcomes in patients with larger cavities and thus warrants further investigation. Several prior studies suggest that this approach is both technically feasible and safe in brain metastasis resection cavities and other intracranial tumors. Although delivering a boost to the residual gross tumor on anatomic MRI represents a reasonable initial strategy, more accurate delineation of metabolically active tumor may require advanced imaging modalities.

**Limitations**

The limitations of this study are largely related to its single-institution, retrospective nature. First, despite the large size of the overall cohort, high rates of local control resulted in only 20 total cases of local tumor recurrence, which limits the statistical power of subgroup analyses. Thus, the findings of this study with respect to cavities of radio-resistant histology should be considered as hypothesis-generating rather than definitive. Second, local tumor recurrence was defined by clinical judgment when biopsy was not indicated or performed. In such circumstances, the ground truth cannot be definitively ascertained. Third, given that our institution was an early adopter of postoperative SRS to brain metastasis resection cavities, doses prescribed earlier in the study period were more conservative than our current institutional prescription of 24 to 27 Gy in 3 fractions. Although a wider range of prescriptions provides a statistical

| Table 3 | Results of univariate Cox regression and final multivariate Cox model assessing predictors of local recurrence |
|---------|--------------------------------------------------------------------------------------------------|
| Variable | Univariate | Multivariate |
|         | HR          | 95% CI       | P      | HR          | 95% CI       | P      |
| Age, y  | 0.99        | 0.95-1.03    | .64    | 0.33        | 0.09-1.22    | .10    |
| Female sex | 1.24        | 0.49-3.11    | .65    | 4.03        | 0.84-19.3    | .08    |
| Infratentorial location | 1.10        | 0.32-3.76    | .88    | 3.28        | 1.09-9.83    | .03    |
| Radio-resistant | 0.56        | 0.19-1.68    | .30    | 1.73        | 0.40-7.50    | .46    |
| Prior radiation to same lesion | 2.13        | 0.28-16.0    | .46    | 1.02        | 0.99-1.05    | .18    |
| Parallel chemotherapy | 0.49        | 0.14-1.67    | .25    | 3.10        | 1.12-8.57    | .03    |
| Parallel immunotherapy | 0.65        | 0.09-4.86    | .67    | 0.99        | 0.93-1.05    | .67    |
| Parallel chemotherapy or immunotherapy | 0.48        | 0.16-1.45    | .19    | 0.96        | 0.76-1.21    | .72    |
| Time from surgery to SRS, mo | 0.98        | 0.58-1.65    | .94    | 0.97        | 0.79-1.20    | .80    |
| Subtotal resection | 1.73        | 0.40-7.50    | .46    | 0.97        | 0.91-1.05    | .49    |
| PTV volume, cm<sup>3</sup> | 1.02        | 0.99-1.05    | .18    | 0.95        | 0.74-1.21    | .68    |
| PTV volume >12 cm<sup>3</sup> | 3.10        | 1.12-8.57    | .03    | 3.28        | 1.09-9.83    | .03    |
| PTV coverage, % | 0.99        | 0.93-1.05    | .67    | 0.96        | 0.76-1.21    | .72    |
| Conformity index | 0.97        | 0.79-1.20    | .80    | 0.95        | 0.74-1.21    | .68    |
| NCI | 0.97        | 0.79-1.20    | .80    | 0.95        | 0.74-1.21    | .68    |
| Number of intact brain metastases treated concurrently | 0.95        | 0.74-1.21    | .68    | 0.95        | 0.74-1.21    | .68    |

**Abbreviations:** CI = confidence interval; HR = hazard ratio; NCI = new conformity index; PTV = planning target volume; SRS = stereotactic surgery.

All variables with P < .7 on univariate analysis were included in the initial multivariate model. Variables that did not improve the Akaike Information Criterion were excluded from the final multivariate model. Bold indicates statistical significance at P < .05.
advantage, yielding richer dose-response models, overall local control rates in this population may not reflect current regimens. Nonetheless, this study was based on high-quality data obtained from one of the largest single-institution series of SRS for brain metastasis resection cavities described to date. All patients included in this study received follow-up MRI after SRS, and the median time to latest imaging follow-up was more than 12 months in patients who did not have local recurrence within the first year. Thus, this study represents an important contribution to the literature despite its limitations.

From a broader perspective, this study suggests that higher doses may yield superior local control for large and radio-resistant cavities but was not intended to rigorously evaluate the corresponding risk of adverse effects. Our research group previously performed normal tissue complication probability modeling to assess the risk of symptomatic radionecrosis in a large cohort of patients who received SRS for intact and resected brain

Figure 2 Tumor control probability models for radio-sensitive and radio-resistant resection cavities. Logistic curves describe the relationship between local tumor control at 1 year after stereotactic surgery (SRS) and dose to the PTV in 3-fraction equivalents. Local control of radio-sensitive (A, B) and radio-resistant (C, D) cavities versus $D_{\text{max}}$ (A, C) and $D_{95\%}$ (B, D) are shown. Similar dose-response relationships were detected for $D_{0.03 \text{ cm}^3}$, $D_{50\%}$, $D_{90\%}$, and $D_{99\%}$ among radio-sensitive cavities (Fig E1) and radio-resistant cavities (Fig E2).
metastases, which included the cases presented in this study. This and similar studies have quantified the likelihood of neurotoxicity as a function of dose to the healthy brain parenchyma and have identified clinically meaningful benchmarks with implications for treatment planning. Given the potential benefits of treating resection cavities with SRS at higher doses, particularly when employing fractionated regimens, continued quantification of adverse radiation effects is needed to assess the therapeutic index of this modality.

Figure 3  Tumor control probability models for large radio-resistant resection cavities (planning target volume [PTV] >12 cc). Logistic curves describe the relationship between local tumor control at 1 year after stereotactic surgery (SRS) and dose to the PTV in 3-fraction equivalents. \( D_{\text{max}} \) (A), \( D_{50\%} \) (B), \( D_{90\%} \) (C), and \( D_{95\%} \) (D) are shown here. Additional models for \( D_{0.03 \text{ cm}^3} \) and \( D_{99\%} \) are provided (Fig E3).

**Conclusions**

This study presents the first quantitative evaluation of tumor control probability as a function of radiation dose after SRS for brain metastasis resection cavities. Consistent with the literature, larger cavities in this cohort were at greater risk of local recurrence. Tumor control probability modeling suggested that higher radiation doses were associated with substantially greater rates of local control, particularly among resection cavities of radio-resistant
histology but not among cavities of radio-sensitive histology. Given established maximum tolerated doses for single-fraction treatments, these data suggest that, although single-fraction SRS may provide excellent local control when treating small targets, fractionated regimens may be required to optimize local control in patients with large radio-resistant cavities.

Supplementary data

Supplementary material for this article can be found at https://doi.org/10.1016/j.adro.2020.06.007.

References

1. Brown PD, Ballman KV, Cerhan JH, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease NCCTG N107C/CEC: 3: A multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18:1049-1060.

2. Mahajan A, Ahmed S, McAleer MF, et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: A single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18:1040-1048.

3. Iorio-Morin C, Masson-Côté L, Ezahr Y, Blanchard J, Ebacher A, Mathieu D. Early Gamma Knife stereotactic radiosurgery to the tumor bed of resected brain metastasis for improved local control. J Neurosurg. 2014;121:69-74.

4. Rava P, Rosenberg J, Jamorabo D, et al. Feasibility and safety of cavity-directed stereotactic radiosurgery for brain metastases at a high-volume medical center. Adv Radiat Oncol. 2016;1:141-147.

5. Jensen CA, Chan MD, McCoy TP, et al. Cavity-directed radiotherapy as adjuvant therapy after resection of a brain metastasis. J Neurosurg. 2011;114:1585-1591.

6. Ojerholm E, Lee JY, Thawani JP, et al. Stereotactic radiosurgery to the resection bed for intracranial metastases and risk of leptomeningeal carcinomatosis. J Neurosurg. 2014;121:75-83.

7. Hartford AC, Paravati AJ, Spire WJ, et al. Postoperative stereotactic radiosurgery without whole-brain radiation therapy for brain metastases: Potential role of preoperative tumor size. Int J Radiat Oncol Biol Phys. 2013;85:650-655.

8. Brennan C, Yang TJ, Hilden P, et al. A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases. Int J Radiat Oncol Biol Phys. 2014;88:130-136.

9. Doré M, Martin S, Delpón G, et al. Stereotactic radiotherapy following surgery for brain metastasis: Predictive factors for local control and radionecrosis. Cancer Radiother. 2017;21:4-9.

10. Abuodeh Y, Ahmed KA, Naghavi AO, et al. Postoperative stereotactic radiosurgery using 5 Gy × 5 sessions in the management of brain metastases. World Neurosurg. 2016;90:58-65.

11. Ahmed KA, Frelich JM, Abuodeh Y, et al. Fractionated stereotactic radiotherapy to the post-operative cavity for radiosensitive and radiosensitive brain metastases. J Neurooncol. 2014;118:179-186.

12. Patel KR, Burri SH, Asher AL, et al. Comparing preoperative with postoperative stereotactic radiosurgery for resectable brain metastases: A multi-institutional analysis. Neurosurgery. 2015;77:279-285.

13. Luther N, Kondziolka D, Kano H, et al. Predicting tumor control after resection bed radiosurgery of brain metastases. Neurosurgery. 2013;73:1001-1006.

14. Steinmann D, Maertens B, Janssen S, et al. Hypofractionated stereotactic radiotherapy hSRT after tumour resection of a single brain metastasis: Report of a single-centre individualized treatment approach. J Cancer Res Clin Oncol. 2012;138:1523-1529.

15. Prahha R, Shu HK, Hadijanianis C, et al. Current dosing paradigm for stereotactic radiosurgery alone after surgical resection of brain metastases needs to be optimized for improved local control. Int J Radiat Oncol Biol Phys. 2012;83:e61-e66.

16. Bilger A, Milanovic D, Lorenz H, et al. Stereotactic fractionated radiotherapy of the resection cavity in patients with one to three brain metastases. Clin Neurol Neurosurg. 2016;142:81-86.

17. Zhong J, Ferris MF, Switchenko J, et al. Postoperative stereotactic radiosurgery for resected brain metastases: A comparison of outcomes for large resection cavities. Pract Radiat Oncol. 2017;7:e419-e425.

18. Strauss I, Com BW, Krishna V, et al. Patterns of failure after stereotactic radiosurgery of the resection cavity following surgical removal of brain metastases. World Neurosurg. 2015;84:1825-1831.

19. Choi CY, Chang SD, Gibbs IC, et al. Stereotactic radiosurgery of the postoperative resection cavity for brain metastases: Prospective evaluation of target margin on tumor control. Int J Radiat Oncol Biol Phys. 2012;84:336-342.

20. Choi CY, Chang SD, Gibbs IC, et al. What is the optimal treatment of large brain metastases? An argument for a multidisciplinary approach. Int J Radiat Oncol Biol Phys. 2012:84:688-693.

21. Minniti G, Espósito V, Clarke E, et al. Multidose stereotactic radiosurgery 9 Gy × 3 of the postoperative resection cavity for treatment of large brain metastases. Int J Radiat Oncol Biol Phys. 2013;86:623-629.

22. Cleary RK, Meshman J, Dewan M, et al. Postoperative fractionated stereotactic radiosurgery to the tumor bed for surgically resected brain metastases. Cureus. 2017;9:e1279.

23. Specht HM, Kessel KA, Oechsner M, et al. HFSRT of the resection cavity in patients with brain metastases. Strahlenther Onkol. 2016;192:368-376.

24. Shin SM, Vatner RE, Tam M, et al. Resection followed by involved-field fractionated radiotherapy in the management of single brain metastasis. Front Oncol. 2015;5:206.

25. Robbins JR, Ryu S, Kalkanis S, et al. Radiosurgery to the surgical cavity as adjuvant therapy for resected brain metastasis. Neurosurgery. 2012;71:937-943.

26. Sollys SG, Adler RR, Lipani JD, et al. Stereotactic radiosurgery of the postoperative resection cavity for brain metastases. Int J Radiat Oncol Biol Phys. 2008;70:187-193.

27. Ling DC, Vargo JA, Wegner RE, et al. Postoperative stereotactic radiosurgery to the resection cavity for large brain metastases: Clinical outcomes, predictors of intracranial failure, and implications for optimal patient selection. Neurosurgery. 2014;76:150-157.

28. Ogíwara H, Kalakota K, Rakhra SS, et al. Intracranial relapse rates and patterns, and survival trends following post-resection cavity radiotherapy for patients with single intracranial metastases. J Neurooncol. 2012;108:141-146.

29. Shi S, Sandhu N, Jin MC, et al. Stereotactic radiosurgery for resected brain metastases: Single-institutional experience of over 500 cavities. Int J Radiat Oncol Biol Phys. 2020;106:764-771.

30. Soliman H, Myrehaug S, Tseng CL, et al. Image-guided, linac-based, surgical cavity-hypofractionated stereotactic radiotherapy in 5 daily fractions for brain metastases. Neurosurgery. 2019;85:E860-E869.

31. Gui C, Moore J, Grimm J, et al. Local recurrence patterns after postoperative stereotactic radiation surgery to resected brain metastases: A quantitative analysis to guide target delineation. Pract Radiat Oncol. 2018;8:388-396.

32. Hoefnagels FW, Lagerwaard FJ, Sanchez E, et al. Radiological progression of cerebral metastases after radiosurgery: Assessment of perfusion MRI for differentiating between necrosis and recurrence. J Neuro. 2009;256:878.

33. Shaw E, Scott C, Souhami L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors.
and brain metastases: Final report of RTOG protocol 90-05. *Int J Radiat Oncol Biol Phys.* 2000;47:291-298.

34. Brown PD, Brown CA, Pollock BE, et al. Stereotactic radiosurgery for patients with “radioresistant” brain metastases. *Neurosurgery.* 2002;51:656-667.

35. Soliman H, Ruschin M, Angelov L, et al. Consensus contouring guidelines for postoperative completely resected cavity stereotactic radiosurgery for brain metastases. *Int J Radiat Oncol Biol Phys.* 2018;100:436-442.

36. Nakamura JL, Verhey LJ, Smith V, et al. Dose conformity of gamma knife radiosurgery and risk factors for complications. *Int J Radiat Oncol Biol Phys.* 2001;51:1313-1319.

37. Paddick I. A simple scoring ratio to index the conformity of radiosurgical treatment plans. *J Neurosurg.* 2000;93(Suppl 3):219-222.

38. R Core Team. *R: A language and environment for statistical computing.* Vienna, Austria: R Foundation for Statistical Computing; 2018. URL https://www.R-project.org/.

39. Wiggenraad R, Verbeek-de Kanter A, Kal HB, et al. Dose–effect relation in stereotactic radiotherapy for brain metastases. A systematic review. *Radiother Oncol.* 2011;98:292-297.

40. Grimm J, Sahgal A, Soltys SG, et al. Estimated risk level of unified stereotactic body radiation therapy dose tolerance limits for spinal cord. *Semin Radiat Oncol.* 2016;26:165-171.

41. Soltys SG, Seiger K, Modlin LA, et al. A phase I/II dose-escalation trial of 3-fraction stereotactic radiosurgery SRS for large resection cavities of brain metastases. *Int J Radiat Oncol Biol Phys.* 2015;93: S38.

42. Tomé WA, Fowler JF. Selective boosting of tumor subvolumes. *Int J Radiat Oncol Biol Phys.* 2000;48:593-599.

43. Amsbaugh MJ, Dunlap NE, Boling W, et al. Simultaneous integrated boost using stereotactic radiosurgery for resected brain metastases: Rationale, dosimetric parameters, and preliminary clinical outcomes. *J Community Support Oncol.* 2015;13:214-218.

44. Cho KH, Kim JY, Lee SH, et al. Simultaneous integrated boost intensity-modulated radiotherapy in patients with high-grade gliomas. *Int J Radiat Oncol Biol Phys.* 2010;78:390-397.

45. Mehrabian H, Detsky J, Soliman H, et al. Advanced magnetic resonance imaging techniques in management of brain metastases. *Front Oncol.* 2019;9:440.

46. Peng L, Grimm J, Gui C, et al. Updated risk models demonstrate low risk of symptomatic radionecrosis following stereotactic radiosurgery for brain metastases. *Surg Neurol Int.* 2019;10:32.

47. Ma TM, Grimm J, McIntyre R, et al. A prospective evaluation of hippocampal radiation dose volume effects and memory deficits following cranial irradiation. *Radiother Oncol.* 2017;125:234-240.

48. Faruqi S, Ruschin M, Soliman H, et al. Adverse radiation effect after hypofractionated stereotactic radiosurgery in 5 daily fractions for surgical cavities and intact brain metastases. *Int J Radiat Oncol Biol Phys.* 2020;106:772-779.